AdAlta Ltd (ASX:1AD) has secured a first Chinese patent relating to its lead idiopathic pulmonary fibrosis (IPF) program, AD-214, from the China National Intellectual Property Administration.
The clinical stage biotechnology company developing novel therapeutic products from its i-body platform has secured Patent Number CN 107427574 B, named 'CXCR4 binding molecules', which expires on January 8, 2036.
This new patent protects the i-body sequence used in AdAlta’s lead product, AD-214, along with sequences similar to this, and pharmaceutical compositions and derivatives containing these i-body sequences.
The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), which AD-214 is being designed to tackle.
Fastest growing market
“China is now the second largest and fastest growing pharmaceutical market in the world after the US, representing 11% of the global prescription drug market,” AdAlta’s CEO and managing director Dr Tim Oldham said.
“IPF is included in the Chinese Rare Diseases List – including it as part of China’s plan to increase availability of drugs for rare diseases. Patent protection for AD-214 in this important market is anticipated to further increase the already significant interest from potential China partners.”
Patents to be pursued in EU and India
Patents are granted on a country-by-country basis, and China is the fifth country to grant patent protection under this application, following Australia (two patents), the US (two patents), Japan and Singapore.
The company is pursuing patent claims in other major markets, including the European Union and India.